Free Trial
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Neurocrine Biosciences logo
$141.33 +1.24 (+0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$141.52 +0.19 (+0.14%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Advanced

Key Stats

Today's Range
$138.79
$142.59
50-Day Range
$128.89
$146.67
52-Week Range
$84.23
$154.61
Volume
673,655 shs
Average Volume
846,818 shs
Market Capitalization
$14.02 billion
P/E Ratio
41.81
Dividend Yield
N/A
Price Target
$163.72
Consensus Rating
Moderate Buy

Company Overview

Neurocrine Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

NBIX MarketRank™: 

Neurocrine Biosciences scored higher than 90% of companies evaluated by MarketBeat, and ranked 68th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    Neurocrine Biosciences has a consensus price target of $163.72, representing about 15.8% upside from its current price of $141.33.

  • Amount of Analyst Coverage

    Neurocrine Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Neurocrine Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Neurocrine Biosciences are expected to grow by 51.17% in the coming year, from $4.28 to $6.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurocrine Biosciences is 41.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 41.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurocrine Biosciences is 41.81, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.71.

  • Price to Earnings Growth Ratio

    Neurocrine Biosciences has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Neurocrine Biosciences has a P/B Ratio of 5.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Neurocrine Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    4.30% of the outstanding shares of Neurocrine Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Neurocrine Biosciences has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Neurocrine Biosciences has recently increased by 3.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Neurocrine Biosciences does not currently pay a dividend.

  • Dividend Growth

    Neurocrine Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.30% of the outstanding shares of Neurocrine Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Neurocrine Biosciences has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Neurocrine Biosciences has recently increased by 3.40%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Neurocrine Biosciences has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Neurocrine Biosciences this week, compared to 17 articles on an average week.
  • Search Interest

    Only 4 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,440,164.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Neurocrine Biosciences is held by insiders.

  • Percentage Held by Institutions

    92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurocrine Biosciences' insider trading history.
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBIX Stock News Headlines

Elon Musk is on the line
Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare.tc pixel
See More Headlines

NBIX Stock Analysis - Frequently Asked Questions

Neurocrine Biosciences' stock was trading at $136.50 at the beginning of the year. Since then, NBIX stock has increased by 3.5% and is now trading at $141.33.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Wednesday, July, 30th. The company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.08. Neurocrine Biosciences's revenue was up 16.5% compared to the same quarter last year.
Read the conference call transcript
.

Neurocrine Biosciences' board initiated a stock buyback program on Friday, February 21st 2025, which allows the company to repurchase $500,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 4.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its stock is undervalued.

Top institutional shareholders of Neurocrine Biosciences include Swedbank AB (0.55%), Allspring Global Investments Holdings LLC (0.39%), Rice Hall James & Associates LLC (0.10%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.10%). Insiders that own company stock include Neurocrine Biosciences Inc, Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Eric Benevich, William H Rastetter, Darin Lippoldt, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Eiry Roberts, Julie Cooke, Jude Onyia, David W Boyer, Ingrid Delaet, Shalini Sharp, Leslie V Norwalk and George J Morrow.
View institutional ownership trends
.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Humana (HUM), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/30/2025
Today
10/20/2025
Next Earnings (Estimated)
10/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NBIX
CIK
914475
Employees
1,800
Year Founded
1992

Price Target and Rating

High Price Target
$195.00
Low Price Target
$115.00
Potential Upside/Downside
+15.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.38
Trailing P/E Ratio
41.81
Forward P/E Ratio
33.02
P/E Growth
1.01
Net Income
$341.30 million
Net Margins
13.88%
Pretax Margin
21.00%
Return on Equity
13.22%
Return on Assets
9.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.20
Quick Ratio
3.10

Sales & Book Value

Annual Sales
$2.36 billion
Price / Sales
5.95
Cash Flow
$3.41 per share
Price / Cash Flow
41.45
Book Value
$25.58 per share
Price / Book
5.53

Miscellaneous

Outstanding Shares
99,180,000
Free Float
94,917,000
Market Cap
$14.02 billion
Optionable
Optionable
Beta
0.21

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:NBIX) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners